DNA methylation of RUNX3 in papillary thyroid cancer

Korean Journal of Internal Medicine

Volumn 27, Issue 4, 2012, Pages 407-410

  Ko, Hee Ja ^a   Kim, Bo Yeon ^a   Jung, Chan Hee ^a   Chun, Sung Wan ^a   Mok, Ji Oh ^a   Kim, Yeo Joo ^a   Park, Hyeong Kyu ^a   Kim, Chul Hee ^a   Kim, Sang Jin ^a   Byun, Dong Won ^a   Suh, Kyo Il ^a   Yoo, Myung Hi ^a   Kang, Sung Gu ^a  

^a Soonchunhyang University College of Medicine   (South Korea)

Author keywords

Methylation; RUNX3; Thyroid neoplasms

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; GENOMIC DNA; TRANSCRIPTION FACTOR RUNX3; TUMOR MARKER;

ARTICLE; CANCER CELL CULTURE; CANCER TISSUE; CARCINOGENESIS; CONTROLLED STUDY; DIAGNOSTIC VALUE; DNA METHYLATION; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; THYROID PAPILLARY CARCINOMA;

METHYLATION; RUNX3; THYROID NEOPLASMS;

AZACITIDINE; CARCINOMA; CELL LINE, TUMOR; CORE BINDING FACTOR ALPHA 3 SUBUNIT; DNA METHYLATION; GENE EXPRESSION; HUMANS; THYROID NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84871745369     PISSN: 12263303     EISSN: 20056648     Source Type: Journal    
DOI: 10.3904/kjim.2012.27.4.407     Document Type: Article

References (20)

1. Coffman JA. Runx transcription factors and the developmental balance between cell proliferation and differentiation. Cell Biol Int 2003;27:315-324.
2. Blyth K, Cameron ER, Neil JC. The RUNX genes: gain or loss of function in cancer. Nat Rev Cancer 2005;5:376-387.
3. Bae SC, Ogawa E, Maruyama M, et al. PEBP2 alpha B/mouse AML1 consists of multiple isoforms that possess differential transactivation potentials. Mol Cell Biol 1994;14:3242-3252.
4. Levanon D, Negreanu V, Bernstein Y, Bar-Am I, Avivi L, Groner Y. AML1, AML2, and AML3, the human members of the runt domain gene-family: cDNA structure, expression, and chromosomal localization. Genomics 1994;23:425-432.
5. Avraham KB, Levanon D, Negreanu V, et al. Mapping of the mouse homolog of the human runt domain gene, AML2, to the distal region of mouse chromosome 4. Genomics 1995;25:603-605.
6. Li QL, Ito K, Sakakura C, et al. Causal relationship between the loss of RUNX3 expression and gastric cancer. Cell 2002;109:113-124.
7. Oshimo Y, Oue N, Mitani Y, et al. Frequent loss of RUNX3 expression by promoter hypermethylation in gastric carcinoma. Pathobiology 2004;71:137-143.
8. Goel A, Arnold CN, Tassone P, et al. Epigenetic inactivation of RUNX3 in microsatellite unstable sporadic colon cancers. Int J Cancer 2004;112:754-759.
9. Araki K, Osaki M, Nagahama Y, et al. Expression of RUNX3 protein in human lung adenocarcinoma: implications for tumor progression and prognosis. Cancer Sci 2005;96:227-231.
10. Li QL, Kim HR, Kim WJ, et al. Transcriptional silencing of the RUNX3 gene by CpG hypermethylation is associated with lung cancer. Biochem Biophys Res Commun 2004;314:223-228.
11. Li J, Kleeff J, Guweidhi A, et al. RUNX3 expression in primary and metastatic pancreatic cancer. J Clin Pathol 2004;57:294-299.
12. Al-Sukhun S, Hussain M. Molecular biology of transitional cell carcinoma. Crit Rev Oncol Hematol 2003;47:181-193.
13. Orntoft TF, Wolf H. Molecular alterations in bladder cancer. Urol Res 1998;26:223-233.
14. Hwang KT, Han W, Bae JY, et al. Downregulation of the RUNX3 gene by promoter hypermethylation and hemizygous deletion in breast cancer. J Korean Med Sci 2007;22 Suppl:S24-S31.
15. Xiao WH, Liu WW. Hemizygous deletion and hypermethylation of RUNX3 gene in hepatocellular carcinoma. World J Gastroenterol 2004;10:376-380.
16. Esteller M. CpG island hypermethylation and tumor suppressor genes: a booming present, a brighter future. Oncogene 2002;21:5427-5440.
17. Guo WH, Weng LQ, Ito K, et al. Inhibition of growth of mouse gastric cancer cells by Runx3, a novel tumor suppressor. Oncogene 2002;21:8351-8355.
18. Cohen MM Jr. TGF beta/Smad signaling system and its pathologic correlates. Am J Med Genet A 2003;116A:1-10.
19. Weinberg RA. The retinoblastoma protein and cell cycle control. Cell 1995;81:323-330.
20. Sherr CJ. Cancer cell cycles. Science 1996;274:1672-1677.